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Abstract: Over the past 6 years, next-generation sequenc-
ing (NGS) has been established as a valuable high-
throughput method for research in molecular genetics 
and has successfully been employed in the identifica-
tion of rare and common genetic variations. Although 
the high expectations regarding the discovery of new 
diagnostic targets and an overall reduction of cost have 
been achieved, technological challenges in instrument 
handling, robustness of the chemistry, and data analysis 
need to be overcome. Each workflow and sequencing plat-
form have their particular problems and caveats, which 
need to be addressed. Regarding NGS, there is a variety 
of different enrichment methods, sequencing devices, or 
technologies as well as a multitude of analyzing software 
products available. In this manuscript, the authors focus 
on challenges in data analysis when employing different 
target enrichment methods and the best applications for 
each of them.
Keywords: bioinformatics; data analysis; molecular 
genetic diagnostics; next-generation sequencing (NGS).
Zusammenfassung: In den vergangenen 6 Jahren hat 
sich “next generation sequencing” (NGS) als wichtige 
Hochdurchsatz-Methode für die molekulargenetische 
Forschung etabliert und wurde erfolgreich zur Identi-
fikation seltener und häufiger genetischer Varianten 
eingesetzt. Während die hohen Erwartungen hinsi-
chtlich der Entdeckung neuer diagnostischer Zielstruk-
turen und einer Senkung der Kosten erreicht wurden, 
müssen etliche technologische Herausforderungen 
hinsichtlich Bedienung der Geräte, Robustheit der Che-
mie und Handhabung der Datenanalyse noch gemeis-
tert werden. Jedes Anreicherungsverfahren und jede 
Sequenzierplattform haben ihre spezifischen Probleme 
und Herausforderungen, die man in Betracht ziehen 
muss. In Bezug auf „next generation sequencing“ gibt 
es neben einer Anzahl verschiedener Anreicherungs-
methoden, Sequenziergeräten und –techniken auch 
eine Vielzahl von unterschiedlicher Auswertesoftware. 
In diesem Artikel richten die Autoren ihr Augenmerk vor 
allem auf die Schwierigkeiten in der Datenanalyse der 
verschiedenen Anreichungsverfahren und deren best-
mögliche Verwendung.
Schlüsselwörter: Bioinformatik; Datenanalyse; moleku-
largenetische Diagnostik; next generation sequencing 
(NGS).
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Introduction – basic data analysis 
caveats
With the emergence of next-generation sequencing (NGS), 
the analysis of huge amounts of data becomes increasingly 
important. The quality and the validity of the detected 
variants vary greatly with the conditions of the library 
preparation process and the sequencing run. Addition-
ally, data analysis has to be tailored to the specific work-
flow (amplicon based, enrichment based, whole exome, 
or genome) and the employed sequencing instruments. 
Each workflow and sequencing platforms have their par-
ticular problems and caveats, which need to be addressed. 
Platform-specific differences have been extensively dis-
cussed in previous publications of our group and others 
[1, 2]. In this work, we focus on challenges in data analysis 
when employing different target-enrichment methods.
Alignment
The basic task of sequence alignment is the mapping of 
millions of short read fragment from about 50 bp to 900 bp 
to reference sequences that may comprise the complete 
human genome. Various issues, e.g., variation in base 
quality, repeat content, or other sequence properties, can 
influence the correct alignment. Consequently, it is impor-
tant to choose the appropriate settings and the correct ref-
erence sequence for each method.
Tag sequence and read trimming
Nonspecific tag sequences generally have to be removed 
from the read. Particularly at the end of reads, the tag 
sequence may pose problems due to its variation in 
length, possibly leading to false positives in the variant 
call (Figure 1). Usually, software provide options for 
finding this kind of sequences, which can be used to trim 
all kinds of adaptor sequences, tag sequences, and primer 
sequences.
Furthermore, read trimming after demultiplexing is 




Figure 1 Schematic overview of a ROCHE454 amplicon structure.
The 454A and 454B adaptors are usually already trimmed by the 454 
software.
in the first few bases and toward the end of the read. 
Different types of trimming can be performed based on 
quality scores, stretches of Ns and a specified number of 
bases at either the 3′ or 5′ end of the reads.
Repeat content and homologous regions
In general, the exact target region needs to be validated, 
and homologous sequences like pseudogenes have to be 
excluded from further analysis. These regions similar to 
the region of interest (ROI) can cause false-positive results 
due to misalignment of sequence reads. This can be 
avoided either by assay design or at the alignment level. 
In the case of amplicon-based target enrichment, similar 
to Sanger sequencing, target-specific primers need to be 
designed. Discrimination at the alignment level has to be 
made for enrichment by oligonucleotide hybridization 
and capturing. This requires software that is able to map 
all given reads to the entire human genome. Additionally, 
a local alignment strategy (Smith-Waterman like algo-
rithm [3, 4]) is needed for amplicon-based target enrich-
ment, while a global alignment (Needleman-Wunsch-like 
algorithm [5]) is required for enrichment by oligonucleo-
tide hybridization and capturing. Moreover, the penalty 
settings for mismatches and gaps of the algorithm are 
a necessary tool to precisely discriminate homologous 
sequences. Another indication for homologous regions 
are reads that can be mapped equally well to different 
genomic locations. We recommend a software that is able 
to flag these reads as multiple matches and ignore them 
during further analysis.
Illumina paired-end sequencing (Illumina, San Diego, 
CA, USA [6]) offers an additional feature, which can be 
exploited to distinguish target gene regions from highly 
similar regions. Reads whose corresponding paired read 
could not be mapped or was mapped outside the accepta-
ble insert size parameters are marked as broken pair. This 
can also be caused by large deletions, insertions, or any 
genomic rearrangements. These reads should be ignored 
during subsequent analysis in a diagnostic setting and 
should not contribute to variant calling (Figure 2).
Variant calling
Variant calling is the next crucial step in the analysis 
of NGS data. Variants are identified by comparing the 
aligned short reads to the reference genome. The variants 
may either be causative for disease, or they may simply 
represent benign genomic variation without a functional 
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effect. The standard format for storing and exchanging 
sequence variation (including SNVs, indels, and larger 
structural variations) is the so-called variant call format 
(VCF). The main challenge of variant call is to distinguish 
true genomic variants from sequencing errors and arti-
facts. The capability to accurately identify genomic varia-
tion is a crucial step in the detection of disease-associated 
mutations. There are several factors that can interfere 
with variant detection. First, the presence of short inser-
tions and deletions may lead to false-positive SNV iden-
tification, especially if the chosen alignment algorithm 
is unable to perform a gapped alignment. Second, PCR 
artifacts introduced during the library preparation may 
be falsely called as variants. Last, sequencing quality 
gradually degrades over the read. In consequence, this 
means that lower-quality bases tend to accumulate toward 
the end of the read, which may lead to erroneous variant 
calls [7].
Forward reverse read balance
As a true-positive variant would be expected to be read 
from both directions, the forward and reverse read balance 
is a measure of the validity of a certain variant call. If 
the variant is observed in just one type of the reads, this 
might be an indication for a sequencing error or an arti-
fact. Paired-end amplicon sequencing is a clear exception 
Figure 2 Screenshots of the CLCbio Genomics Workbench.
Reads mapped in pairs are indicated by blue, reads with unmapped paired-end read are indicated by red and green (broken pairs).  
(A) A false-positive variant call with the variant allele primarily present in broken reads is highlighted in green between the black lanes.  
(B) A validated variant call, with the variant allele primarily present in paired-end reads is highlighted in green.
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to this, as reads may not overlap and are only sequenced 
from one direction.
Insertions, deletions, and indels
The detection of insertion, deletions, and indels, where 
a deletion and an insertion occur at the same position, 
is more challenging than calling point mutations. The 
detectable length of these variations strongly depends on 
the mapping algorithm used because the penalty scores 
for mismatches, insertions, and deletions vary between 
them. Some software even made these parameters vari-
able, so the user can influence the mapping. Small events 
of up to about 25 bp are able to be called on a sequence-
dependent manner; larger variants need more complex 
approaches based on split read alignment or insert size 
analysis [8]. In a diagnostic setting, we recommend more 
standardized methods like multiplex ligation-dependent 
probe amplification (MLPA) or array-comparative genomic 
hybridization (aCGH) for detecting these larger variants.
Data analysis
Regarding NGS, there is a variety of different enrichment 
methods, sequencing devices, or technologies as well as a 
multitude of analyzing software products available. Most 
applications are compatible with each other, and it is up 
to the operator to choose them reasonably.
Amplicon-based sequencing (TSCA)
First, a multiplexing approach with the TruSeq Custom 
Amplicon (TSCA) Kit (Illumina, San Diego, CA, USA) was 
used to sequence a gene panel of 17 genes known to cause 
early infantile epileptic encephalopathy (EIEE), combined 
with sequencing on the Illumina MiSeq.
The “TruSeq Amplicon” approach uses two independ-
ent left and right flanking oligonucleotides, which are 
hybridized to a genomic DNA template enabling polymer-
ase extension and ligation. The flanking oligonucleotides 
contain universal sequences for step-out PCR and incor-
poration of universal barcoded Illumina adapters [9]. A 
total of 370 oligonucleotide pairs for 188 coding exons 
and bordering intronic regions, totaling approximately 
50 kb of cumulative sequence, was easily designed with 
the Design Studio Web-based tool (Illumina, San Diego, 
CA, USA). Amplicons of 250 bp length were amplified in 
a single reaction, and library preparation was finished 
within 2 days. Five of the 188 total exons failed the probe 
design (2.6%). Redesign of the failed exons by slightly 
modifying the chromosomal region did not improve the 
results. The capture is very scalable, as all steps can be 
performed in a 96-well PCR plate and can be semiauto-
mated by liquid handling.
A panel of samples with known point mutations, small 
deletions, and duplications were sequenced in a MiSeq 
run that produced 5.5 Gb of sequence. Quality control 
(QC) of sequence data obtained from NGS technologies is 
extremely important for meaningful downstream analy-
sis. The FASTQC Toolkit [10] was used for quality check 
and filtering of high-quality data. The mean sequencing 
quality score (Q-score) was over 30 in 88.2% of the data. 
The Q-score is a prediction of the probability of an incor-
rect base call. A higher quality score implies that a base 
call is more reliable and less likely to be incorrect [11]. For 
base calls with a Q-score of 30, one base call in 1000 is 
predicted to be incorrect. We observed a marked drop-off 
quality (Q < 20) in the last 50 to 80 bases of the read in some 
amplicons within each dataset. Another common artifact 
of the TruSeq Amplicon technology is the miscalling of the 
first two bases of the read, thus, increasing the number 
of false positives. Different end trimming of the reads was 
applied on each data set. In a diagnostic setting, trim-
ming of low-quality bases at both ends of the reads (mean 
Q < 20) should be performed to achieve analysis of high-
quality data. Our analysis confirmed the variant in all but 
four indels that could not be detected with the standard 
parameters.
Mapping with the BWA software [12] showed very 
equal distribution of mapped reads between sample 
sets. Mean coverage was  > 500-fold. Overall, 95% of the 
target sequence was covered at more than 40 × . Seven 
of 188 exons (3.7%) had a coverage between 20 ×  to 40 × , 
and five exons (2.6%) failed amplification in most of the 
cases. These were very reproducible between samples. 
The minimal coverage for diagnostic criteria was 40 ×  and 
Q > 20. All fragments which did not achieve these criteria 
were inspected manually, and an individual decision was 
taken for subsequent analysis with Sanger sequencing. As 
base Q-score is often correlated with the complexity of the 
DNA sequence, manual inspection of the alignment with 
a visualization tool helps to estimate whether a called 
variant is a true- or a false- positive call. We observed a 
high rate of false-positive variants in the range of Q20 
to Q30. The major source of false-positive variants arises 
through either miss-incorporation of bases during PCR 
amplification. When using a PCR-amplicon approach, all 
reads align with the same start location based on primer 
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design and, therefore, extraction of PCR duplicate reads 
cannot be performed. Designing overlapping PCR ampli-
cons and accepting only consensus variant calls between 
amplified intervals may help to reduce this problem.
Variant calls are first annotated with snpEff [9] and 
intersected with dbSNP [13], Exome Sequencing Project 
(ESP) [14], COSMIC data [15], and our in-house mutation 
database. In addition, we use features from the Alamut-
HT software (Interactive Biosoftware, Rouen, France) to 
help with data interpretation and predict the mutation 
effects on splice sites and protein function.
Probe ligation-based DNA fragment  
enrichment (HaloPlex™)
The HaloPlex™ Target Enrichment Kit provided by Agilent 
Technologies (Agilent Technologies, CA, USA) was com-
bined with sequencing on the Illumina MiSeq and data 
analysis with SeqNext of JSI medical systems (JSI medical 
systems, Kippenheim, Germany).
The HaloPlex™ Target Enrichment System is based on 
probe hybridization and circularization of enzymatically 
digested DNA. In contrast to other hybridization-based 
methods, each probe is an oligonucleotide designed to 
hybridize to both ends of a targeted DNA restriction frag-
ment, so that the fragments are able to form circular DNA 
molecules. A PCR step enables the enrichment of perfectly 
ligated and barcoded fragments plus an incorporation of 
standard Illumina paired-end sequencing motifs. The com-
plete workflow to capture a target region from 1 to 500 kb 
takes about 1 day and capturing a target region from 500 kb 
to 5 Mb about 1.5 days. This procedure results in millions of 
fragments that are all constructed in the following order: 
Illumina sequencing motif – barcode sequence – univer-
sal primer sequence – region of interest – universal primer 
sequence – Illumina sequencing motif [16].
With this setup, it is achievable to produce about 
4 Gb of sequencing data with a 2 × 150 paired end run on 
the MiSeq. On average, there are 80% of the data above a 
quality value of Q30, which demonstrates a good quality 
compared to competing devices. With the MiSeq Reporter, 
it is possible to generate demultiplexed raw data files 
(fastq format), which can be loaded directly into the 
SeqNext software. Alternatively, the data can be aligned 
to the human genome and, afterwards, imported into the 
SeqNext Software.
Before the data is loaded into the program, the opera-
tor is able to make some preliminary settings. For example, 
poor quality data can be excluded from the analysis by 
specifying a quality score threshold. This depends on the 
quality score graph of each MiSeq run. The adapters can 
be trimmed by entering the universal primer sequence 
in the corresponding field; bases between the universal 
primer sequences are retained for further analysis. Addi-
tional bases at the fragment ends that do not match the 
reference can also be removed automatically by a user 
input.
Main preferences, which affect mutation calling and 
the sorting of variants to distinct or not distinct (“other”) 
variations, can be done at the beginning of the setting 
tab. The user may enter an absolute coverage value if 
this coverage level has to be reached in both sequencing 
directions together or separately. Positions with an abso-
lute coverage below the entered value are not called. Fur-
thermore, it is possible to specify a ratio read direction. 
Afterwards, the user has to select a minimal coverage line. 
Positions with coverage below the entered value will get a 
warning for this region. Variations that pass the main filter 
settings will be classified into distinct or not distinct vari-
ations depending on variant frequency and user-defined 
thresholds. This enables the user to exclude mosaicism. 
Finally, the user can specify in which cases a variation in 
a homopolymeric region should be listed, in the distinct 
tab or in the homopolymer tab.
In this setting, we used an absolute coverage of five, 
a minimum coverage line of 20, and a minimal variant 
frequency of 15%. The minimum base quality threshold 
was set at 20, yet an average base quality of the individ-
ual variant could not be displayed because this option 
was not available in the software. The SeqNext software 
annotates the detected variants with HGVS Nomenclature, 
even historical nomenclature, dbSNP rs-identifiers, and a 
custom-made database (editable and correlated with in-
house Sanger data).
The resulting variants were filtered and screened 
against previously detected variants, dbSNP, 1000 
Genomes [17], and HGMD® professional (Biobase, Wolfen-
buettel, Germany).
Enrichment by oligonucleotide-based 
sequencing (TSCE)
For the (TSCE) library preparation, one standard workflow 
was established and validated. Data analysis is performed 
with the CLC Genomics Workbench (CLCbio, Aarhus, 
Denmark) and custom-developed Perl scripts (Figure 3).
Using the Illumina Design Studio tool, a total of 5860 
probes were designed for a total of 5365 target regions. 
Success rate of the probes was estimated at  ≥  95%. The 
library preparation followed the Nextera® Enrichment 
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Sample Preparation Guide and was finished within 2.5 
days. All steps are performed in a 96-well plate.
The mapping was performed with the global align-
ment algorithm. Two to three percent of the reads 
could not be mapped to the human genomic reference 
assembly (hg19), while 6–11% of the mapped reads were 
so-called broken reads and, thus, ignored for variant 
calling. The coverage was  ≥  20 ×  in 93.52–96.73% of the 
regions. Of the exons, 105 of 4018 (2.6%) failed over all 
samples. The probes fishing these regions need to be 
redesigned. We defined all bases with a coverage level of 
20 ×  or more suitable for variant calling. In conclusion, 
we determined that an average coverage level of 80–120 ×  
is optimal for variant calling. While an increase in cov-
erage to ∼200 ×  does not yield significant improvements 
in the number of bases covered at 20 ×  or more, a drop 
in average coverage to ∼40 ×  results in significantly less 
bases covered at 20 × .
Validation experiments with a set of samples with 





















Figure 3 Analysis pipeline, schematic overview.
Analysis steps are performed with the CLC Genomics Workbench 
and custom developed Perl scripts. Exons with one or more low 
coverage bases ( < 20) are reanalyzed by Sanger sequencing.
For variant detection, the probabilistic variant caller 
implemented in the CLCbio Genomics Workbench is used. 
The caller works with a Bayesian model and a maximum 
likelihood algorithm to calculate the probabilities of 
candidate variants. All potential mutations and vari-
ants of unknown significance are confirmed by Sanger 
sequencing. All variants above a Q-Value of 27 have been 
confirmed by Sanger sequencing, while no variant with 
a Q-Value below 24 could be confirmed. Variants with a 
Q-Value between 25 and 27 are in a twilight zone. In these 
cases, the quality of the reference base and the surround-
ing bases and the region characteristics (e.g., homopoly-
mer region) are decisive to estimate whether it is a true 
variant or a false-positive call (Figure 4). The variant call 
is annotated with GTF-Files for exon numbering, coding 
region change, and gene information. The Genome Trax™ 
module of Biobase can be used in the CLCbio software for 
annotating all variants with additional information like 
HGMD®, COSMIC database [15], dbNSFP [18], PGX, GWAS 
data, Online Mendelian Inheritance in Man (OMIM®, Bal-
timore, MD, USA) information, and experimentally verified 
transcription factor-binding sites (TFBS). On the last step, 
the information from dbSNP common flagged and the 
entire dbSNP is added. This allows a very specific filtering 
for any individual indication. For instance, in the case of 
dominant disorders, the dbSNP common will be filtered 
away, while for recessive disorders, the filtering of the 
known SNPs has to be adjusted to the incidence rate of 
the analyzed disease. This list of variants will be inspected 
for the interpretation of the result. The procedure is as 
follows: if a variant is found, which is already reported in 
literature and even in the HGMD® database or any other 
disease-related database (e.g., Leiden Open Variation 
Database (LOVD [19]), then, the variant is confirmed with 
Sanger sequencing. If a variant with unknown signifi-
cance is found, in silico prediction tools like Pholyphen2 
[20], MutationTaster [21], SIFT [22], etc., will be used to 
estimate the pathogenicity, and all putative disease-caus-
ing mutations are confirmed by Sanger sequencing. If no 
Figure 4 True insertion of a Cytosin in a homopolymer region.
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causative variant is found, all regions, which are below 
20 ×  coverage, need to be sequenced by Sanger.
Whole-exome-based sequencing (WES)
For whole-exome sequencing data analysis, several 
mapping, variant calling, and annotation workflows are 
applied. The filtering strategy mainly consists of two stages, 
a variant-based and a gene annotation-based filtering. The 
first filtering step includes a genotype and a population 
frequency filter. The genotype filter removes all variants 
that are not in accordance with the clinical history and the 
pedigree information. The population frequency filter then 
removes all frequent variants based on the global allele 
frequency (GAF) score from the 1000 Genomes Project 
and an in-house allele frequency database. In this second 
filtering step, all remaining variants are linked to expert-
curated and literature data mining-based disease anno-
tations (Figure 5). With this strategy and MESH disease 
ontologies, it is possible to link causative variants to the 
clinical diagnoses. Finally, the data has to be visualized to 
be interpreted, validated, and reported to the requesting 
physician. Important parameters to follow-up on a variant 
are covered over this particular variant, genotype quality 
(GQ), protein effect, the gene and exon(s) affected, or the 
publications supporting the gene-disease link and segre-
gation analysis within the family.
Taken together, pedigree analyses in combina-
tion with clinical information, background population 








Figure 5 Filtering of variants in three different datasets (log scale).
For each filtering step the number of remaining variants and the 
filter factor is given. The filters are (i) gene body (variants that 
overlap with a transcript), (ii) deleterious (variants that alter the 
protein sequence or hit a canonical splice-site), (iii) GT (genotype 
filter derived from the medical report), (iv) MAF (1000 genomes 
background filter), and (v) disease (filter for the primary disease and 
MESH parents from the medical report).
frequencies, and disease annotations provide a powerful 
information basis to find the needle in the haystack.
Applications
The use of NGS technologies has been mainly limited to 
research facilities, but new sequencing devices with a 
lower throughput and a high quality of sequencing data 
enables now the application of these technologies in 
genetic diagnostics. By using NGS, it is possible to sequence 
several genes simultaneously, in a cost-effective and time-
saving manner. Especially multigene panel diagnostic is 
a very powerful tool to identify the causative mutation 
for heritable diseases that are genetically heterogeneous 
and can only be assigned to a group of diseases because 
of their clinical variability, for example, muscular disor-
ders or neuropathies. A variety of enrichment methods 
is available on the market to design custom gene panels. 
Each laboratory should decide depending not only on the 
disease/gene panel characteristics but also on the labora-
tory facilities, which is the best approach. In this section, 
we will discuss the experiences with the amplicon-based 
TruSeq and HaloPlex systems, the custom enrichment-
based approach for larger gene panels (TruSeq custom 
enrichment, TSCE), and whole-exome sequencing.
Amplicon based/HaloPlex™
TruSeq Amplicon and HaloPlex™ products have several 
advantages in sample preparation compared to other 
enrichment methods. Both methods combine the speed 
of PCR with the sensitivity of hybridization providing 
a robust solution for targeting smaller capture regions 
in  < 2 days. Another positive aspect is that standard labo-
ratory devices and no additional laboratory equipment 
are needed. Furthermore, the operator is able to follow 
always the same laboratory protocol, so it is possible to 
combine different gene panels in one enrichment step. 
Robotics is not necessary to complete the sample prepa-
ration, but protocols can be easily automated. Our expe-
riences showed that automation of the protocols not 
only increases reproducibility between samples but also 
enables higher throughput, and it is less time-consuming 
and avoids sample mix-up [2].
We recommend using these approaches for small 
gene panels. Our design for the TSCA kit contains 50 kb 
of cumulative sequence, but new versions of the TSCA kit 
can cover up to 650 kb with 1536 amplicons per reaction. 
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However, this is a multiplex approach, and raising the 
number of oligonucleotid primer pairs might decrease the 
overall efficiency of PCR amplification. The HaloPlex™ 
has two different protocols for 1 to 500 kb and 500 kb to 
5 Mb. So far, we tested different panel sizes with 170-, 217-, 
and 615-kb target region.
Both kits, TruSeq Amplicon and HaloPlex™, support 
multiplexing of up to 96 different samples. In combination 
with a MiSeq sequencer, we can parallel sequence several 
patients in a 2 × 150-bp run in a single standard flow cell 
(28 tiles). Recently, Illumina has launched the Nano 
(eight tiles) and Micro (two tiles) flow cells, which differ 
in output and number of tiles imaged. This offers the user 
more flexibility when planning the number of samples to 
be sequenced in a run. The number of sequencing cycles 
when using an amplicon approach will depend on the 
amplicon length. In contrast to shot-gut library sequenc-
ing, which accepts different sequencing read lengths, the 
number of cycles when sequencing amplicon products 
has to be maintained for the same gene panel unless the 
length of the amplicon is changed in a new amplicon 
design. Using HaloPlex™, it is possible to decide during 
the order process between a read length of 100, 150, and 
250 bps.
Coverage variability in PCR enrichment approaches 
is often observed in regions with an elevated number of 
SNPs, deletions, and high GC content due to bias on failed 
oligonucleotide design or PCR amplification. A disadvan-
tage of the amplicon-based technology is the difficulty in 
improving enrichment of low-coverage regions because 
primer design and PCR amplification is strongly limited 
by the complexity of the DNA sequence.
One last advantage of the HaloPlex™-based enrich-
ment approach has to be mentioned at this point. With 
HaloPlex™, each target is covered by multiple amplicons. 
If an unknown variation occurs in a restriction site, it may 
affect only a few fragments and not every fragment in this 
region. This minimizes allelic dropouts, and the variation 
can be called correctly due to the filter setting of the ana-
lyzing software.
Overall, the TruSeq and HaloPlex™ PCR-based 
enrichment methods are mainly recommended for diag-
nostic screening of small gene panels. Small gene panels 
can be designed for diseases with moderate heterogeneity 
or for phenotypes that can be well characterized within a 
subpanel of genes in high heterogeneous diseases. Main-
taining a small number of genes in the design facilitates 
data analysis in terms of speed and complexity, as well as 
the interpretation of the variant calls. Further analysis of 
low-coverage/low-quality regions with a second method 
(Sanger sequencing) in addition to the number of variants 
to be confirmed will be moderate, and accurate analysis 
of the complete region can be implemented within a few 
days.
Enrichment based
The most widespread application of target enrichment by 
oligonucleotide hybridization followed by NGS is targeted 
diagnostics using gene panels. Using this approach, all 
genes with known or implicated contribution to a specific 
indication are simultaneously enriched and sequenced. In 
comparison to Sanger sequencing, a lot of cost and labor 
can be saved, yet, the same diagnostic standard may be 
retained by choosing appropriate quality parameters. 
Target sequences that fail to reach these quality thresh-
olds have to be resequenced by an alternative method [2, 
23].
In comparison to amplicon-based enrichment 
methods, hybridization-based methods employ multiple 
oligonucleotide probes, which are complementary to the 
genomic target regions to capture and enrich all regions 
of interest. Prior to enrichment, the genome is randomly 
fragmented, either enzymatically or by sonication. As 
most of the target regions are covered by more than one 
capture probe, this enables an even coverage, while mini-
mizing PCR artifacts and potentially compensating for 
single enrichment probe failures. Enrichment efficiency is 
influenced by the underlying sequence properties like GC 
and repeat content [24, 25]. In contrast to amplicon-based 
approaches, the enrichment is quantitative, resulting in 
increased off-target effects. Employing this approach, we 
generate 60–75% reads that are on target.
With this method, modest size region starting from 
approximately 500 kb to 25 Mb of sequence can be 
enriched (TSCE), rendering the method most useful in the 
diagnostics of very heterogeneous disorders with a variety 
of possible candidate genes, for example, arrythmogenic 
cardiac disorders or hearing impairments. Using combina-
tions of different MIDs, multiplexing for up to 96 samples/
run is possible.
Coverage variability in enrichment-based approaches 
is observed in regions with a high GC content or in a 
homologous region due to the probe-binding affinities 
or of the probes-nonspecific binding, respectively. Thus, 
it is difficult to increase enrichment in regions of low 
coverage, which is a definite disadvantage of the TSCE 
technology or any other enrichment-based approach. 
The advantage is that there are no taq sequences to be 
trimmed, leading to fewer discrepancies at the mapping 
and variant calling.
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In conclusion, the TruSeq Custom Enrichment method 
is mainly recommended for diagnostic screening of large 
gene sets. Large gene panels can be designed for diseases 
with high heterogeneity or for phenotypes difficult to 
assign clinically. Especially for these large gene panels, 
time and cost can be saved in comparison to Sanger 
sequencing. Further analysis of low-coverage regions with 
a second method (Sanger sequencing) in addition to the 
number of potential disease-causing variants to be con-
firmed will be moderate.
Whole exome based
For whole-exome enrichment, an in-solution hybridiza-
tion-based technology is used. The target region can vary 
between 40 and up to 70 Mb depending on exons, flank-
ing regions, and UTRs to be included. With every whole-
exome enrichment, a small percentage (2–3%) of the target 
region is not covered sufficiently for reliable SNV calling 
due to several reasons (regions of high homology, GC-rich 
regions, etc.). Usually, a mean coverage of 150–200 ×  is 
recommended on the Illumina HiSeq. Increasing the 
number of reads per exome does not necessarily help to 
target regions with low coverage as this is due to reduced 
efficiency in the enrichment and not in the sequencing 
process.
Diagnostic reporting
Diagnostically reporting of the NGS-based result has to 
take additional criteria into account in comparison to the 
Sanger-based reports. Technical details such as the target 
region (exons, flanking regions, UTRs), the enrichment 
assay, the sequencing platform, the analysis software, 
and quality settings should be specified in the method 
section. Furthermore, the target regions achieving the cri-
teria have to be declared. Regions not passing the criteria 
are analyzed by another method if necessary. Exon dele-
tion and duplication has to be excluded as well as intronic 
regulatory SNPs. It has to be mentioned that the effect of 
unknown synonymous SNPs with regard to exonic splicing 
enhancer (ESE) motifs is uncertain and not predictable.
There is strong preference to only report known or 
likely pathogenic variants as no universally accepted 
guidelines exist for reporting of all detected variants 
of unknown significance and incidental findings. By 
gene panel diagnostic, the amount of unknown vari-
ants and incidental findings is reduced in comparison to 
whole-exome sequencing. Reporting is an ongoing dis-
cussion, and the reports should follow the general inter-
national standards of the UK Clinical Molecular Genetics 
Society (CMGS) and the Swiss Society of Medical Genetics 
(SSMG).
Outlook – regulatory SNPs  
and CNVs
Regulatory SNPs and exonic splicing 
enhancer (ESEs)
There are many regulatory elements in the genome, 
which are difficult to predict. Thus, they have not been 
sequenced in a Sanger testing. But with the coming of the 
NGS and different enrichment methods, it is possible to 
sequence larger UTR and intronic regions. There are a few 
algorithms to predict mutations in splice sites and regu-
latory elements like Human Splicing Finder, Transfac® 
(Biobase), and MatInspector (Genomatix). The additional 
analysis of these regions causes a huge extension of the 
data analysis time and an expertise to judge the result of 
these programs.
Copy number variations (CNVs)
In addition to the identification of point mutations 
and small insertion or deletion events in patients’ DNA 
samples, NGS allows also to detect gene copy number 
variants (CNVs). The resolution for the detection of CNVs 
ranges from a single base pair up to nonoverlapping 
windows of several hundred base pairs. Challenging due 
to the experimental variability, a more coarsened resolu-
tion will result in more robust candidate regions, which 
are less sensitive against outliers and, moreover, easier to 
interpret. The detection windows may be evenly distrib-
uted across the genome with a fixed window size, or, as 
array comparative genomic hybridization (aCGH) profil-
ing is currently the gold standard for genetic diagnosis of 
CNVs [26], the partitioning of the genome may be based on 
the chromosomal coordinates of the microarray probes. 
This approach additionally allows direct comparison of 
both methods [27]. In the case of targeted sequencing 
(e.g., exomes, gene panels), the chromosomal coordi-
nates of either the region of interest or the baits used for 
enrichment are preferential limiters of detection windows. 
Figure 6 shows the principle of CNV detection using a read 
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depth-based approach comparing a tumor sample and 
the corresponding germline sample to identify regions of 
altered gene copies. In a rather homogenous cell popula-
tion, possible somatic gene copy changes are two-copy 
loss, one-copy loss, one-copy gain, and two-copy gain, 
resulting in hypothetical coverage ratios of 0.0, 0.5, 1.5, 
and 2.0.
Owing to the variability of the enrichment efficiency, 
the detection of CNVs using targeted sequencing, as 
well as calling somatic copy number alterations (CNAs), 
implicitly requires a germline control of the same 
patient for comparison. The distribution of the detec-
tion windows must be equal in both samples to match 
the read depth of the test and the control sample and 
to compute a ratio on the coverage. Simple fold change 
approaches are the easiest way to detect CNVs, but are 
neither capable to handle regions of zero coverage nor to 
detect mono-allelic deletions. This problem may be over-
come using mathematical modeling approaches, e.g., a 
linear regression model [28]. Further detection strategies 
are based on (i) the size of the chromosomal region that 
is spanned by paired-end reads, (ii) separate mapping of 
both ends of a read to detect insertions/deletions result-
ing in CNVs, and (iii) de novo assembly of reads to small 
pieces of contigs [29].
To further enhance the reliability of in silico deter-
mined CNVs using detection tools based on NGS, puta-
tive CNVs may be correlated to well-established routine 
methods like fluorescence in situ hybridization (FISH) 
or multiplex ligation-dependent probe amplification 
(MLPA). Anyway, it was published recently that calling 
CNVs using Illumina NGS is comparable in performance 
to aCGH [27], supporting its possible supersession in the 
future as calling mutations on the sequence level (point 
mutations, insertions, deletions, indels) and on a dosage 
level (CNVs) at once will notably reduce time effort and 
costs in clinical diagnostics.
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Figure 6 Example of a CNA detected on NGS data in a tumor/normal sample pair.
(A) Visualization of sequence reads mapped to exon sites and resulting read depth. Upper panel indicates normal sample, lower panel 
indicates tumor sample with copy number loss of exon B by ∼50%. Gray horizontal bars, sequence reads; black horizontal line, intronic/
intergenic sites; black boxes, exon regions. (B) Example of de novo detection of coverage ratios on the same exons. Ratio of ∼0.5 indicates 
1 somatic copy loss of the corresponding region. Blue horizontal bars, equivalent coverage in both samples; red horizontal bars, somatic 
read depth loss; x-axis, genomic position; y-axis, coverage ratios between tumor and normal sample.
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